Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1690

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 1690
---
 capital markets. There have also been
disruptions to the U.S. banking system due to bank failures in the past several years, including with respect to Silicon Valley Bank,
Signature Bank and First Republic Bank. Any such volatility and disruptions may have adverse consequences on us or the third parties on
whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary
debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Increased inflation
rates can adversely affect us by increasing its costs, including labor and employee benefit costs. In addition, higher inflation could
also increase customers’ operating costs, which could result in reduced budgets for customers and potentially less demand for our
products, if and when approved. Any significant increases in inflation and related increase in interest rates could have a material adverse
effect on our business, results of operations and financial condition.

87

We do not intend to pay dividends on our
Common Stock, so any returns will be limited to the value of our stock.

We currently anticipate that
we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying
any cash dividends for the foreseeable future. In addition, future debt or other financing arrangements may contain terms prohibiting
or limiting the amount of dividends that may be declared or paid on our Common Stock. Any return to stockholders will therefore be limited
in the foreseeable future to the appreciation of the market price (if any) of our stock.

We are an “emerging growth company”
and a “smaller reporting company”, and the reduced reporting requirements applicable to emerging growth companies and smaller
reporting companies may make our Common Stock less attractive to investors.

We are an “emerging
growth company” within the meaning of the Securities Act, as modified by the JOBS Act. For as long as we continue to be an emerging
growth company, we may take advantage of certain exemptions from various public company reporting requirements that are applicable to
other public companies that are not emerging growth companies, including being permitted to provide only two years of audited financial
statements, in addition to any required unaudited interim financial statements with correspondingly reduced “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” disclosure, not being required to have its internal control
over financial reporting audited by our independent registered public accounting firm under Section 404 of the Sarbanes-O